Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer

Michael R Shafique, Lary A Robinson, Scott Antonia Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87...

Full description

Bibliographic Details
Main Authors: Shafique MR, Robinson LA, Antonia S
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:Cancer Management and Research
Subjects:
Non-small cell lung cancer
maintenance therapy
staging
immunotherapy
chemoradiation
surgery-ineligible
durvalumab
Online Access:https://www.dovepress.com/durvalumab-a-potential-maintenance-therapy-in-surgery-ineligible-non-s-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/durvalumab-a-potential-maintenance-therapy-in-surgery-ineligible-non-s-peer-reviewed-article-CMAR

Similar Items